{"type":"trials","record":{"id":41469,"source_id":"clinicaltrials-gov","external_id":"NCT06680817","title":"A Real-World Study to Gain Clinical Insights Into Faricimab (FaReal Study)","brief_summary":"The FaReal study aims to evaluate the effectiveness, safety, clinical insights and treatment patterns in patients treated with faricimab, in neovascular age-related macular degeneration (nAMD) or diabetic macular edema (DME) in at least one eye, in real-world routine clinical practice over a 2-year patient follow-up period. Additionally, the FaReal study also aims to describe and evaluate health economic aspects of previous anti-VEGF treatments and current treatment with faricimab.","overall_status":"Active Not Recruiting","phases":[],"study_type":"OBSERVATIONAL","sponsor":"Hoffmann-La Roche","enrollment":850,"countries":["Austria","Bulgaria","Czechia","Finland","Greece","Hungary","Ireland","Israel","Latvia","Netherlands","Poland","Portugal","Romania","Slovakia","Slovenia"],"start_date":"2025-02-05","completion_date":"2028-06-30","last_update_date":"2026-07-07","source_url":"https://clinicaltrials.gov/study/NCT06680817","editorial_summary":"A registered study indexed because it matched monitored longevity research terms. Registry status: Active Not Recruiting. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T01:25:30.378222+00:00","last_seen_at":"2026-09-25T06:20:47.789+00:00","metadata":{"sex":"ALL","acronym":null,"age_range":"18 Years","comparator":null,"organization":"Hoffmann-La Roche","interventions":["Faricimab"],"registry_source":"ClinicalTrials.gov","outcome_measures":["Change in Visual Acuity from Index Date to 12 Months — Index Date and 12 months","Change in Visual Acuity from Index Date to 3, 6, and 24 Months — Index Date and 3, 6, and 24 months","Change in Central Subfield Thickness (CST) from Index Date to 3, 6, 12, and 24 Months — Index Date and 3, 6, 12, and 24…","Percentage of Eyes on Each Treatment Regimen (Fixed, Treat-and-Extend, As Needed, or Other) Over Time — Index Date and…","Number of Faricimab Intravitreal Injections per Eye per Year — 12 and 24 months","Number of Faricimab Intravitreal Injections in the Loading Phase for Participants who are anti-VEGF Treatment Naive or…","Total Number of Visits and Number of Visits With or Without Treatment Over Time — 3, 6, 12, and 24 months","Cumulative Time Spent in Each Treatment Regimen (Fixed, Treat-and-Extend, As Needed, or Other) — From Index Date to 24…","Percentage of Eyes With Treatment Switch from Faricimab by Reason for Switch in Participants who are anti-VEGF Treatmen…","Percentage of Eyes Obtaining Treatment Intervals of Once Every 8, 12, or 16 Weeks or Other Intervals in Participants wh…","Change in Visual Acuity from Index Date Over Time, According to Treatment Regimen (Fixed, Treat-and-Extend, As Needed,…","Change in Visual Acuity from Index Date Over Time, According to Number of Intravitreal Treatments — Index Date and 3, 6…","Change in Visual Acuity from Index Date Over Time, According to Total Number of Visits — Index Date and 3, 6, 12, and 2…","Change in Visual Acuity from Index Date Over Time, According to Treatment Intervals — Index Date and 3, 6, 12, and 24 m…","Change in Visual Acuity from Index Date Over Time, According to Type of anti-VEGF Pre-Treatment and Number of Previous…","Change in Visual Acuity from Index Date Over Time, According to Length of Diagnosis of Disease at Index Date — Index Da…","Number of Participants with at Least One Ocular Adverse Event — Approximately 2 years","Number of Participants with at Least One Non-Ocular Adverse Event — Approximately 2 years"],"design_description":null,"source_has_results":false},"controlled_terms":["Neovascular Age-related Macular Degeneration","Diabetic Macular Edema","Faricimab"],"relevance_confidence":100,"source_quality_score":100,"freshness_score":100,"publication_state":"published","match_explanation":"Abstract contains controlled term: age-related macular degeneration.","quality_checked_at":"2026-09-25T06:20:59.355028+00:00","duplicate_cluster_key":"id:nct06680817","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2025-02-05 to 2028-06-30","comparator":null,"confidence":"structured-source","population":"ALL · 18 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:20:47.818Z","intervention":["Faricimab"],"participants":850,"study_design":"OBSERVATIONAL","subject_scope":"Human clinical study registration","evidence_stage":"Phase not reported","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["Change in Visual Acuity from Index Date to 12 Months — Index Date and 12 months","Change in Visual Acuity from Index Date to 3, 6, and 24 Months — Index Date and 3, 6, and 24 months","Change in Central Subfield Thickness (CST) from Index Date to 3, 6, 12, and 24 Months — Index Date and 3, 6, 12, and 24…","Percentage of Eyes on Each Treatment Regimen (Fixed, Treat-and-Extend, As Needed, or Other) Over Time — Index Date and…","Number of Faricimab Intravitreal Injections per Eye per Year — 12 and 24 months","Number of Faricimab Intravitreal Injections in the Loading Phase for Participants who are anti-VEGF Treatment Naive or…","Total Number of Visits and Number of Visits With or Without Treatment Over Time — 3, 6, 12, and 24 months","Cumulative Time Spent in Each Treatment Regimen (Fixed, Treat-and-Extend, As Needed, or Other) — From Index Date to 24…","Percentage of Eyes With Treatment Switch from Faricimab by Reason for Switch in Participants who are anti-VEGF Treatmen…","Percentage of Eyes Obtaining Treatment Intervals of Once Every 8, 12, or 16 Weeks or Other Intervals in Participants wh…","Change in Visual Acuity from Index Date Over Time, According to Treatment Regimen (Fixed, Treat-and-Extend, As Needed,…","Change in Visual Acuity from Index Date Over Time, According to Number of Intravitreal Treatments — Index Date and 3, 6…","Change in Visual Acuity from Index Date Over Time, According to Total Number of Visits — Index Date and 3, 6, 12, and 2…","Change in Visual Acuity from Index Date Over Time, According to Treatment Intervals — Index Date and 3, 6, 12, and 24 m…","Change in Visual Acuity from Index Date Over Time, According to Type of anti-VEGF Pre-Treatment and Number of Previous…","Change in Visual Acuity from Index Date Over Time, According to Length of Diagnosis of Disease at Index Date — Index Da…","Number of Participants with at Least One Ocular Adverse Event — Approximately 2 years","Number of Participants with at Least One Non-Ocular Adverse Event — Approximately 2 years"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"vision-aging","is_published":true,"match_reasons":["Abstract contains controlled term: age-related macular degeneration.","Source terminology contains: age-related macular degeneration.","Abstract supplies longevity context: age-related.","Study type is explicitly identified as OBSERVATIONAL."],"matched_fields":["abstract","controlled terminology","abstract context","study type"],"relevance_score":100,"intelligence_topics":{"name":"Vision ageing","slug":"vision-aging"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/41469","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}